Iovance Biotherapeutics, Inc.
IOVA
$2.45
-$0.08-3.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 636.99% | 11,070.12% | 13,698.99% | 12,751.20% | 13,669.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 636.99% | 11,070.12% | 13,698.99% | 12,751.20% | 13,669.75% |
| Cost of Revenue | 305.14% | 824.04% | 1,052.91% | 1,196.04% | 2,208.98% |
| Gross Profit | 441.67% | 386.77% | 518.93% | 241.49% | -703.64% |
| SG&A Expenses | 28.05% | 50.24% | 43.12% | 35.70% | 22.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.55% | 30.28% | 21.14% | 16.50% | 14.80% |
| Operating Income | 10.59% | 14.69% | 14.17% | 3.67% | -7.21% |
| Income Before Tax | 12.63% | 16.70% | 16.20% | 4.27% | -6.38% |
| Income Tax Expenses | 103.20% | 33.33% | 18.71% | -257.27% | -1,130.19% |
| Earnings from Continuing Operations | 11.43% | 16.52% | 16.18% | 5.31% | -5.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.43% | 16.52% | 16.18% | 5.31% | -5.10% |
| EBIT | 10.59% | 14.69% | 14.17% | 3.67% | -7.21% |
| EBITDA | 12.36% | 17.26% | 17.54% | 7.11% | -3.35% |
| EPS Basic | 27.10% | 32.07% | 31.46% | 28.07% | 25.12% |
| Normalized Basic EPS | 27.81% | 31.92% | 30.90% | 26.80% | 23.80% |
| EPS Diluted | 27.10% | 32.07% | 31.46% | 28.07% | 25.12% |
| Normalized Diluted EPS | 27.81% | 31.92% | 30.90% | 26.80% | 23.80% |
| Average Basic Shares Outstanding | 20.21% | 22.51% | 23.33% | 30.81% | 38.39% |
| Average Diluted Shares Outstanding | 20.21% | 22.51% | 23.33% | 30.81% | 38.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |